Brand Name
Cosopt
Generic Name
Dorzolamide
View Brand Information FDA approval date: June 01, 2009
Classification: Carbonic Anhydrase Inhibitor
Form: Solution
What is Cosopt (Dorzolamide)?
COSOPT ® is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers . The IOP-lowering of COSOPT administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day. COSOPT is a combination of dorzolamide hydrochloride, a carbonic anhydrase inhibitor, and timolol maleate, a beta-adrenergic receptor blocking agent, indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. The IOP-lowering of COSOPT twice daily was slightly less than that seen with the concomitant administration of 0.5% timolol twice daily, and 2% dorzolamide three times daily.
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Efficacy and Tolerability of Simbrinza and Rocklatan vs. Cosopt
Summary: A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.